208 related articles for article (PubMed ID: 34944600)
1. Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia.
Bai Z; Xu M; Mei Y; Hu T; Zhang P; Chen M; Lv W; Lu C; Tan S
Biomedicines; 2021 Nov; 9(12):. PubMed ID: 34944600
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy.
Xu M; Lei G; Chen M; Wang K; Lv W; Zhang P; Hu T; Gao J; Lu C; Mei Y; Xu Z; Bai Z; Hu H; Jiang Y; Tan S
EBioMedicine; 2021 Mar; 65():103250. PubMed ID: 33647772
[TBL] [Abstract][Full Text] [Related]
3. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
[TBL] [Abstract][Full Text] [Related]
4. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
[TBL] [Abstract][Full Text] [Related]
5. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
[TBL] [Abstract][Full Text] [Related]
6. The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats.
Li X; Wang M; Zhang X; Liu C; Xiang H; Huang M; Ma Y; Gao X; Jiang L; Liu X; Li B; Hou Y; Zhang X; Yang S; Yang N
Clin Transl Med; 2020 Feb; 9(1):16. PubMed ID: 32056048
[TBL] [Abstract][Full Text] [Related]
7. In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake.
Ando T; Yamamoto M; Yokoyama T; Horiuchi D; Kawakami T
J Biosci Bioeng; 2021 Mar; 131(3):326-332. PubMed ID: 33177004
[TBL] [Abstract][Full Text] [Related]
8. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
9. A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice.
Essalmani R; Weider E; Marcinkiewicz J; Chamberland A; Susan-Resiga D; Roubtsova A; Seidah NG; Prat A
Biol Chem; 2018 Nov; 399(12):1363-1374. PubMed ID: 30044755
[TBL] [Abstract][Full Text] [Related]
10. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
Schiele F; Park J; Redemann N; Luippold G; Nar H
J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
[TBL] [Abstract][Full Text] [Related]
11. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo.
Ni YG; Di Marco S; Condra JH; Peterson LB; Wang W; Wang F; Pandit S; Hammond HA; Rosa R; Cummings RT; Wood DD; Liu X; Bottomley MJ; Shen X; Cubbon RM; Wang SP; Johns DG; Volpari C; Hamuro L; Chin J; Huang L; Zhao JZ; Vitelli S; Haytko P; Wisniewski D; Mitnaul LJ; Sparrow CP; Hubbard B; Carfí A; Sitlani A
J Lipid Res; 2011 Jan; 52(1):78-86. PubMed ID: 20959675
[TBL] [Abstract][Full Text] [Related]
12. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
13. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia.
Wu C; Xi C; Tong J; Zhao J; Jiang H; Wang J; Wang Y; Liu H
Acta Pharm Sin B; 2019 Nov; 9(6):1216-1230. PubMed ID: 31867167
[TBL] [Abstract][Full Text] [Related]
15. Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin/kexin 9 (PCSK9) on low-density lipoprotein receptor (LDL-R).
Palmer-Smith H; Basak A
Curr Med Chem; 2010; 17(20):2168-82. PubMed ID: 20423303
[TBL] [Abstract][Full Text] [Related]
16. Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cells.
Mousavi SA; Berge KE; Berg T; Leren TP
FEBS J; 2011 Aug; 278(16):2938-50. PubMed ID: 21692990
[TBL] [Abstract][Full Text] [Related]
17. Local effects of human PCSK9 on the atherosclerotic lesion.
Giunzioni I; Tavori H; Covarrubias R; Major AS; Ding L; Zhang Y; DeVay RM; Hong L; Fan D; Predazzi IM; Rashid S; Linton MF; Fazio S
J Pathol; 2016 Jan; 238(1):52-62. PubMed ID: 26333678
[TBL] [Abstract][Full Text] [Related]
18. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.
Chan JC; Piper DE; Cao Q; Liu D; King C; Wang W; Tang J; Liu Q; Higbee J; Xia Z; Di Y; Shetterly S; Arimura Z; Salomonis H; Romanow WG; Thibault ST; Zhang R; Cao P; Yang XP; Yu T; Lu M; Retter MW; Kwon G; Henne K; Pan O; Tsai MM; Fuchslocher B; Yang E; Zhou L; Lee KJ; Daris M; Sheng J; Wang Y; Shen WD; Yeh WC; Emery M; Walker NP; Shan B; Schwarz M; Jackson SM
Proc Natl Acad Sci U S A; 2009 Jun; 106(24):9820-5. PubMed ID: 19443683
[TBL] [Abstract][Full Text] [Related]
19. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
[TBL] [Abstract][Full Text] [Related]
20. AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia.
Somanathan S; Jacobs F; Wang Q; Hanlon AL; Wilson JM; Rader DJ
Circ Res; 2014 Aug; 115(6):591-9. PubMed ID: 25023731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
